Uplisting to a US market soon!
CZO should trade at a much higher price. The problem is the poor liquidity. News like the one we have today should attract the interest of US analysts. The only way to get more liquidity is to issue more shares, like Gilles did in 2016. Long time shareholders remember that this financing was backed by good news and propulsed the stock from around 70 cents to $2.45 in less than 3 months. This move could be repeated easely now since CZO is a more mature co today that it was four years ago. In my opinion, the Market is ready for this kind of financing. The biotech sector is very hot now as we can see with the number of new shares issued by many small canadian companies (with great success).